Financière de Tubize SA EPS
What is the EPS of Financière de Tubize SA?
The EPS of Financière de Tubize SA is 5.85
What is the definition of EPS?
Earnings per share (EPS) is the portion of a company’s profit allocated to each outstanding share of common stock. It is adjusted for dilution and calculated over trailing twelve months.
ttm (trailing twelve months)
Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. Preferred stock rights have precedence over common stock. Therefore, dividends on preferred shares are subtracted before calculating the EPS. When preferred shares are cumulative, annual dividends are deducted whether or not they have been declared. Dividends in arrears are not relevant when calculating EPS. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.
EPS of companies in the Health Care sector on EURONEXT compared to Financière de Tubize SA
What does Financière de Tubize SA do?
Financière de Tubize S.A., through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's principal products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Zyrtec and Xyzal for the treatment of allergy; Nootropil for the treatment of psycho-organic syndromes or cognitive decline and cortical myoclonus; and Xyrem for use in treating narcolepsy with cataplexy in adult patients. The company's products in pipeline include padsevonil for drug resistant epilepsy; UCB0107 for treating progressive supranuclear palsy; UCB0599 for Parkinson's disease; UCB7858 for auto-inflammatory diseases; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize S.A. is based in Brussels, Belgium.
Companies with eps similar to Financière de Tubize SA
- Jost's Engineering has EPS of 5.84
- Blue Star has EPS of 5.85
- Apollo Micro systems has EPS of 5.85
- Cambridge Technology Enterprises has EPS of 5.85
- AMGEN has EPS of 5.85
- WEX Inc has EPS of 5.85
- Financière de Tubize SA has EPS of 5.85
- Northern Oil and Gas has EPS of 5.86
- Stef S.A has EPS of 5.86
- Westlife Development has EPS of 5.86
- Northern Oil and Gas has EPS of 5.86
- J.B. Hunt Transport Services has EPS of 5.86
- e Crit SA has EPS of 5.86